Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis

被引：0
|
作者：
Deng, G. [1 ]
Li, Z. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002P
引用
收藏
页码：S1012 / S1012
页数：1
相关论文
共 50 条
  • [21] Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma
    Wang, H.
    Li, H.
    Zhang, M.
    Zhang, G.
    Zhang, X.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S985 - S985
  • [22] Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma
    Zhu, Hui
    Ma, Xiaoyan
    Yu, Jinming
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1484 - S1484
  • [23] Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
    Ma, Xiaoyan
    Zhu, Hui
    Guo, Hongbo
    Han, Anqin
    Wang, Haiyong
    Jing, Wang
    Zhang, Yan
    Kong, Li
    Yu, Jinming
    ONCOTARGET, 2016, 7 (49) : 81906 - 81917
  • [24] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Lin, Jessica J.
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne E.
    Jackman, David M.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 556 - 565
  • [25] EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
    Liu, Sangtian
    He, Yayi
    Jiang, Tao
    Ren, Shengxiang
    Zhou, Fei
    Zhao, Chao
    Li, Xuefei
    Zhang, Jie
    Su, Chunxia
    Chen, Xiaoxia
    Cai, Weijing
    Gao, Guanghui
    Li, Wei
    Wu, Fengying
    Li, Jiayu
    Zhao, Jing
    Hu, Qiong
    Zhao, Mingchuan
    Zhou, Caicun
    Hirsch, Fred R.
    LUNG CANCER, 2018, 120 : 82 - 87
  • [26] Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs
    Altavilla, Giuseppe
    Arrigo, Carmela
    Tomasello, Chiara
    Santarpia, Mariacarmela
    Mondello, Patrizia
    Benecchi, Sara
    Pitini, Vincenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics (RBIOP-CLICaP)
    Cardona, Andres F.
    Arrieta, Oscar
    Zapata, Martin I.
    Rojas, Leonardo
    Wills, Beatriz
    Carranza, Hernan
    Reguart, Noemi
    Vargas, Carlos
    Otero, Jorge
    Corrales-Rodriguez, Luis
    Martin, Claudio
    Archila, Pilar
    Cuello, Mauricio
    Ortiz, Carlos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S168 - S168
  • [28] Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
    Zhou, Jinhua
    Qin, Hongya
    Miao, Jianlong
    Liu, Ruijuan
    Wang, Wei
    MEDICINE, 2023, 102 (26) : E34110
  • [29] Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
    Wang, H.
    Li, M.
    Xing, R.
    Wei, C.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1110 - S1110
  • [30] Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
    Hongyan Wu
    Fangtian Fan
    Zhaoguo Liu
    Cunsi Shen
    Aiyun Wang
    Yin Lu
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 307 - 315
12345